Immunome, Inc. (IMNM)
Largest Insider Buys in Sector
IMNM Stock Price History Chart
IMNM Stock Performance
About Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Insider Activity of Immunome, Inc.
Over the last 12 months, insiders at Immunome, Inc. have bought $2.82M and sold $279,296 worth of Immunome, Inc. stock.
On average, over the past 5 years, insiders at Immunome, Inc. have bought $2.01M and sold $279,296 worth of stock each year.
Highest buying activity among insiders over the last 12 months: SIEGALL CLAY B (President and CEO) — $4.7M. BIENAIME JEAN JACQUES (director) — $498,991. Tsai Philip (Chief Technology Officer) — $198,030.
The last purchase of 33,943 shares for transaction amount of $331,918 was made by SIEGALL CLAY B (President and CEO) on 2024‑11‑22.
List of Insider Buy and Sell Transactions, Immunome, Inc.
| 2024-11-22 | President and CEO | 33,943 0.0543% | $9.78 | $331,918 | +37.17% | |||
| 2024-11-21 | President and CEO | 66,057 0.1059% | $9.54 | $630,263 | +40.87% | |||
| 2024-11-21 | Chief Technology Officer | 21,000 0.0333% | $9.43 | $198,030 | +40.87% | |||
| 2024-11-21 | Chief Medical Officer | 15,805 0.0252% | $9.48 | $149,800 | +40.87% | |||
| 2024-09-19 | Sale | Chief Financial Officer | 14,380 0.0251% | $16.01 | $230,224 | -17.99% | ||
| 2024-08-16 | director | 7,000 0.0128% | $13.94 | $97,608 | 0.00% | |||
| 2024-08-15 | Sale | Chief Scientific Officer | 3,524 0.0064% | $13.93 | $49,072 | 0.00% | ||
| 2024-05-21 | President and CEO | 20,434 0.0344% | $13.78 | $281,548 | -0.73% | |||
| 2024-05-21 | director | 2,000 0.0033% | $13.57 | $27,140 | -0.73% | |||
| 2024-05-20 | President and CEO | 79,566 0.1337% | $13.91 | $1.11M | -1.81% | |||
| 2023-10-02 | President and CEO | 169,204 0.9994% | $5.91 | $999,996 | +76.83% | |||
| 2023-10-02 | Chief Strategy Officer | 42,300 0.2498% | $5.91 | $249,993 | +76.83% | |||
| 2021-09-13 | director | 25,962 0.2086% | $19.96 | $518,202 | -72.24% | |||
| 2021-09-10 | director | 15,500 0.1243% | $17.85 | $276,675 | -68.95% | |||
| 2021-09-09 | director | 30,450 0.2559% | $18.19 | $553,774 | -67.84% | |||
| 2021-05-26 | director | 2,300 0.0194% | $18.94 | $43,562 | -22.31% | |||
| 2021-05-26 | director | 1,335 0.0113% | $19.03 | $25,405 | -22.31% | |||
| 2021-05-25 | director | 19,303 0.167% | $18.32 | $353,631 | -17.32% | |||
| 2021-05-25 | director | 2,715 0.0236% | $18.44 | $50,065 | -17.32% | |||
| 2021-05-25 | President and CEO | 10,500 0.0913% | $18.41 | $193,305 | -17.32% |
Insider Historical Profitability
| SIEGALL CLAY B | President and CEO | 519636 0.8325% | $10.95 | 5 | 0 | |
| Tsai Philip | Chief Technology Officer | 21000 0.0336% | $10.95 | 1 | 0 | |
| BIENAIME JEAN JACQUES | director | 16615 0.0266% | $10.95 | 2 | 0 | |
| Lechleider Robert | Chief Medical Officer | 15805 0.0253% | $10.95 | 1 | 0 | |
| WAGENHEIM PHILIP | director | 397397 0.6367% | $10.95 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Redmile Group | $120.67M | 8.15 | 4.89M | +26.04% | +$24.93M | 1.23 | |
| Fidelity Investments | $111.91M | 7.56 | 4.53M | +16.09% | +$15.51M | 0.01 | |
| Ecor1 Capital Llc | $95.74M | 6.47 | 3.88M | 0% | +$0 | 0.67 | |
| T. Rowe Price | $55.42M | 3.75 | 2.25M | +113.63% | +$29.48M | 0.01 | |
| The Vanguard Group | $49.85M | 3.37 | 2.02M | +16.07% | +$6.9M | <0.01 |